Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline Summary
Year: 2018
Type: article
Abstract: Immune checkpoint inhibitors (ICPi) have revolutionized the treatment of many types of cancers.ICPis work by blocking pathways, called checkpoints, and these checkpoint pathways are mechanisms for the human immune system to control the immune response.The immune checkpoint proteins, cytotoxic T lymphocyte-associated 4 (CTLA-4) and programmed death 1 (PD-1), are receptors that are expressed on the surface of cytotoxic T cells that interact with their ligands-CD80/CD86 in the case of CTLA-4, and programmed death ligand-1 in the case of PD-1.These pathways can be co-opted to help cancer cells evade cytotoxic T cell-mediated death. 1 ICPis prevent receptors and ligands from binding to each other, thereby disrupting signaling.1 Currently, there are several ICPis that have been approved by the US Food and Drug Administration.Ipilimumab, an anti-CTLA-4 antibody, was the first agent approved for use in patients with advanced melanoma.2 Pembrolizumab and nivolumab target PD-1 and have been approved for the treatment of melanoma, metastatic non-small-cell lung cancer, head and neck squamous cancers, urothelial carcinoma, gastric adenocarcinoma, and mismatch repair-deficient solid tumors as well as classical Hodgkin lymphoma.2
Source: Journal of Oncology Practice
DOI: 10.1200/jop.18.00005
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: immune-related adverse events, immune checkpoint inhibitors, CTLA-4, PD-1, PD-L1, ipilimumab, pembrolizumab, nivolumab, cancer immunotherapy, immune checkpoint blockade, melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, urothelial carcinoma, gastric adenocarcinoma, classical Hodgkin lymphoma
Open Access status: bronze
OpenAlex ID: W2789465165
